GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Retained Earnings

Zevra Therapeutics (FRA:1GDA) Retained Earnings : €-383.09 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Zevra Therapeutics's retained earnings for the quarter that ended in Mar. 2024 was €-383.09 Mil.

Zevra Therapeutics's quarterly retained earnings declined from Sep. 2023 (€-318.08 Mil) to Dec. 2023 (€-366.60 Mil) and declined from Dec. 2023 (€-366.60 Mil) to Mar. 2024 (€-383.09 Mil).

Zevra Therapeutics's annual retained earnings declined from Dec. 2021 (€-236.32 Mil) to Dec. 2022 (€-333.92 Mil) and declined from Dec. 2022 (€-333.92 Mil) to Dec. 2023 (€-366.60 Mil).


Zevra Therapeutics Retained Earnings Historical Data

The historical data trend for Zevra Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Retained Earnings Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -221.14 -212.47 -236.32 -333.92 -366.60

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -299.20 -300.37 -318.08 -366.60 -383.09

Zevra Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Zevra Therapeutics  (FRA:1GDA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines